Telomere dysfunction and tumor suppression responses in dyskeratosis congenita: Balancing cancer and tissue renewal impairment

Ageing Research Reviews

Volumn 12, Issue 2, 2013, Pages 642-652

  Hartwig, Fernando Pires ^a   Collares, Tiago ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

ASCs impairment; Cancer; Clinical variability; Dyskeratosis congenita; Telomeres; Tumor suppression

Indexed keywords

DNA; RIBONUCLEOPROTEIN; TELOMERASE;

ADULT STEM CELL; AGING; APOPTOSIS; BONE MARROW DEPRESSION; CANCER GENETICS; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL AGING; CELL PROLIFERATION; CELL RENEWAL; DISEASE MARKER; DNA DAMAGE; DYSKERATOSIS CONGENITA; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; LIFESPAN; LONGEVITY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PREMATURE AGING; PREVALENCE; REVIEW; RISK FACTOR; STEM CELL; TELOMERE;

AGE OF ONSET; AGED; AGING, PREMATURE; BONE MARROW DISEASES; CELL AGING; DYSKERATOSIS CONGENITA; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, THEORETICAL; MUTATION; NEOPLASMS; RISK FACTORS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84876335525     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2013.03.003     Document Type: Review

References (164)

1. Abreu E., Aritonovska E., Reichenbach P., Cristofari G., Culp B., Terns R.M., Lingner J., Terns M.P. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Molecular and Cellular Biochemistry 2010, 30:2971-2982.
2. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., Greider C.W., Harley C.B. Telomere length predicts replicative capacity of human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10114-10118.
3. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557.
4. Alter B.P., Giri N., Savage S.A., Peters J.A., Loud J.T., Leathwood L., Carr A.G., Greene M.H., Rosenberg P.S. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. British Journal of Haematology 2010, 150:179-188.
5. Ara S., Lee P.S., Hansen M.F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Research 1990, 18:4961.
6. Armanios M., Alder J.K., Parry E.M., Karim B., Strong M.A., Greider C.W. Short telomeres are sufficient to cause the degenerative defects associated with aging. American Journal of Human Genetics 2009, 85:823-832.
7. Artandi S.E., Attardi L.D. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochemical and Biophysical Research Communications 2005, 331:881-890.
8. Artandi S.E., Depinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
9. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., Depinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406:641-645.
10. Aviv A. Telomeres and human somatic fitness. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2006, 61:871-873.
11. Bartkova J., Bakkenist C.J., Rajpert-De M.E., Skakkebaek N.E., Sehested M., Lukas J., Kastan M.B., Bartek J. ATM activation in normal human tissues and testicular cancer. Cell Cycle 2005, 4:838-845.
12. Begus-Nahrmann Y., Lechel A., Obenauf A.C., Nalapareddy K., Peit E., Hoffmann E., Schlaudraff F., Liss B., Schirmacher P., Kestler H., Danenberg E., Barker N., Clevers H., Speicher M.R., Rudolph K.L. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nature Genetics 2009, 41:1138-1143.
13. Beier F., Foronda M., Martinez P., Blasco M.A. Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita. Blood 2012, 120:2990-3000.
14. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology 2011, 29:504-515.
15. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg D., Ebert B.L. Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine 2011, 364:2496-2506.
16. Belair C.D., Yeager T.R., Lopez P.M., Reznikoff C.A. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:13677-13682.
17. Bellodi C., Kopmar N., Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO Journal 2010, 29:1865-1876.
18. Bessler M., Wilson D.B., Mason P.J. Dyskeratosis congenita. FEBS Letters 2010, 584:3831-3838.
19. Blackburn E.H. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Letters 2005, 579:859-862.
20. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nature Reviews Genetics 2005, 6:611-622.
21. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
22. Bojovic B., Ho H.Y., Wu J., Crowe D.L. Stem cell expansion during carcinogenesis in stem cell-depleted conditional telomeric repeat factor 2 null mutant mice. Oncogene 2012.
23. Borovski T., De Sousa E.M., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Research 2011, 71:634-639.
24. Calado R.T., Regal J.A., Kleiner D.E., Schrump D.S., Peterson N.R., Pons V., Chanock S.J., Lansdorp P.M., Young N.S. A spectrum of severe familial liver disorders associate with telomerase mutations. PLOS ONE 2009, 4:e7926.
25. Celli G.B., de L.T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nature Cell Biology 2005, 7:712-718.
26. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., Depinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
27. Choudhury A.R., Ju Z., Djojosubroto M.W., Schienke A., Lechel A., Schaetzlein S., Jiang H., Stepczynska A., Wang C., Buer J., Lee H.W., von Z.T., Ganser A., Schirmacher P., Nakauchi H., Rudolph K.L. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nature Genetics 2007, 39:99-105.
28. Cichowski K., Hahn W.C. Unexpected pieces to the senescence puzzle. Cell 2008, 133:958-961.
29. Cooper J.P., Watanabe Y., Nurse P. Fission yeast Taz1 protein is required for meiotic telomere clustering and recombination. Nature 1998, 392:828-831.
30. Cosme-Blanco W., Shen M.F., Lazar A.J., Pathak S., Lozano G., Multani A.S., Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Reports 2007, 8:497-503.
31. d'Adda di F.F. Living on a break: cellular senescence as a DNA-damage response. Nature Reviews Cancer 2008, 8:512-522.
32. d'Adda di F.F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., von Z.T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
33. de Keizer P.L., Laberge R.M., Campisi J. p53: pro-aging or pro-longevity?. Aging (Albany, NY) 2010, 2:377-379.
34. de La Roche Saint-Andre Alternative ends: telomeres and meiosis. Biochimie 2008, 90:181-189.
35. de L.T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes and Develpoment 2005, 19:2100-2110.
36. Denchi E.L., de L.T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007, 448:1068-1071.
37. Deng Y., Chan S.S., Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nature Reviews Cancer 2008, 8:450-458.
38. Diaz de L.A., Cronkhite J.T., Katzenstein A.L., Godwin J.D., Raghu G., Glazer C.S., Rosenblatt R.L., Girod C.E., Garrity E.R., Xing C., Garcia C.K. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLOS ONE 2010, 5:e10680.
39. Dickson S.P., Wang K., Krantz I., Hakonarson H., Goldstein D.B. Rare variants create synthetic genome-wide associations. PLOS Biology 2010, 8:e1000294.
40. Dokal I. Dyskeratosis congenita in all its forms. British Journal of Haematology 2000, 110:768-779.
41. Dokal I. Dyskeratosis congenita. Hematology/American Society of Hematology Education Program Book 2011, 2011:480-486.
42. Dokal I., Vulliamy T., Mason P., Bessler M. Clinical utility gene card for: dyskeratosis congenita. European Journal of Human Genetics 2011, 19.
43. Dokal I., Bungey J., Williamson P., Oscier D., Hows J., Luzzatto L. Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements. Blood 1992, 80:3090-3096.
44. Donate L.E., Blasco M.A. Telomeres in cancer and ageing. Philosophical Transactions of the Royal Society B: Biological Sciences 2011, 366:76-84.
45. Du H.Y., Idol R., Robledo S., Ivanovich J., An P., Londono-Vallejo A., Wilson D.B., Mason P.J., Bessler M. Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome. Aging Cell 2007, 6:689-697.
46. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics 2003, 33:357-365.
47. Espejel S., Franco S., Rodriguez-Perales S., Bouffler S.D., Cigudosa J.C., Blasco M.A. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO Journal 2002, 21:2207-2219.
48. Espejel S., Franco S., Sgura A., Gae D., Bailey S.M., Taccioli G.E., Blasco M.A. Functional interaction between DNA-PKcs and telomerase in telomere length maintenance. EMBO Journal 2002, 21:6275-6287.
49. Feng Z., Lin M., Wu R. The regulation of aging and longevity: a new and complex role of p53. Genes and Cancer 2011, 2:443-452.
50. Ferron S., Mira H., Franco S., Cano-Jaimez M., Bellmunt E., Ramirez C., Farinas I., Blasco M.A. Telomere shortening and chromosomal instability abrogates proliferation of adult but not embryonic neural stem cells. Development 2004, 131:4059-4070.
51. Ferron S.R., Marques-Torrejon M.A., Mira H., Flores I., Taylor K., Blasco M.A., Farinas I. Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. Journal of Neuroscience 2009, 29:14394-14407.
52. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
53. Flores I., Blasco M.A. A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. PLOS ONE 2009, 4:e4934.
54. Flores I., Blasco M.A. The role of telomeres and telomerase in stem cell aging. FEBS Letters 2010, 584:3826-3830.
55. Flores I., Cayuela M.L., Blasco M.A. Effects of telomerase and telomere length on epidermal stem cell behavior. Science 2005, 309:1253-1256.
56. Flores I., Benetti R., Blasco M.A. Telomerase regulation and stem cell behaviour. Current Opinion in Cell Biology 2006, 18:254-260.
57. Flores I., Canela A., Vera E., Tejera A., Cotsarelis G., Blasco M.A. The longest telomeres: a general signature of adult stem cell compartments. Genes and Develpoment 2008, 22:654-667.
58. Gadalla S.M., Cawthon R., Giri N., Alter B.P., Savage S.A. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany, NY) 2010, 2:867-874.
59. Garcia-Cao I., Garcia-Cao M., Tomas-Loba A., Martin-Caballero J., Flores J.M., Klatt P., Blasco M.A., Serrano M. Increased p53 activity does not accelerate telomere-driven ageing. EMBO Reports 2006, 7:546-552.
60. Garcia-Cao I., Garcia-Cao M., Martin-Caballero J., Criado L.M., Klatt P., Flores J.M., Weill J.C., Blasco M.A., Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO Journal 2002, 21:6225-6235.
61. Gire V., Roux P., Wynford-Thomas D., Brondello J.M., Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO Journal 2004, 23:2554-2563.
62. Goldman F., Bouarich R., Kulkarni S., Freeman S., Du H.Y., Harrington L., Mason P.J., Londono-Vallejo A., Bessler M. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:17119-17124.
63. Gonzalez-Suarez E., Samper E., Flores J.M., Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nature Genetics 2000, 26:114-117.
64. Greider C.W. Telomeres do D-loop-T-loop. Cell 1999, 97:419-422.
65. Greider C.W., Blackburn E.H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987, 51:887-898.
66. Gu B.W., Bessler M., Mason P.J. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10173-10178.
67. Guo X., Deng Y., Lin Y., Cosme-Blanco W., Chan S., He H., Yuan G., Brown E.J., Chang S. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO Journal 2007, 26:4709-4719.
68. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
69. Hara E., Tsurui H., Shinozaki A., Nakada S., Oda K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochemical and Biophysical Research Communications 1991, 179:528-534.
70. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
71. Harley C.B., Vaziri H., Counter C.M., Allsopp R.C. The telomere hypothesis of cellular aging. Experimental Gerontology 1992, 27:375-382.
72. Harrington L. Does the reservoir for self-renewal stem from the ends?. Oncogene 2004, 23:7283-7289.
73. Harrington L. Haploinsufficiency and telomere length homeostasis. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2012, 730:37-42.
74. Harris T.J., McCormick F. The molecular pathology of cancer. Nature Reviews Clinical Oncology 2010, 7:251-265.
75. He S., Nakada D., Morrison S.J. Mechanisms of stem cell self-renewal. Annual Review of Cell and Developmental Biology 2009, 25:377-406.
76. Heiss N.S., Knight S.W., Vulliamy T.J., Klauck S.M., Wiemann S., Mason P.J., Poustka A., Dokal I. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature Genetics 1998, 19:32-38.
77. Hellen C.U., Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes and Develpoment 2001, 15:1593-1612.
78. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002, 21:598-610.
79. -/- embryos is associated with failure to close the neural tube. EMBO Journal 1999, 18:1172-1181.
80. Hiyama T., Yoshihara M., Tanaka S., Chayama K. Genetic polymorphisms and head and neck cancer risk (Review). International Journal of Oncology 2008, 32:945-973.
81. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nature Reviews Molecular and Cellular Biology 2005, 6:318-327.
82. Imyanitov E.N. Gene polymorphisms, apoptotic capacity and cancer risk. Human Genetics 2009, 125:239-246.
83. Imyanitov E.N. Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. Mechanisms of Ageing and Development 2009, 130:122-127.
84. Jaskelioff M., Muller F.L., Paik J.H., Thomas E., Jiang S., Adams A.C., Sahin E., Kost-Alimova M., Protopopov A., Cadinanos J., Horner J.W., Maratos-Flier E., Depinho R.A. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2011, 469:102-106.
85. Kirwan M., Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochimica et Biophysica Acta 2009, 1792:371-379.
86. Kirwan M., Beswick R., Walne A.J., Hossain U., Casimir C., Vulliamy T., Dokal I. Dyskeratosis congenita and the DNA damage response. British Journal of Haematology 2011, 153:634-643.
87. Lamm N., Ordan E., Shponkin R., Richler C., Aker M., Tzfati Y. Diminished telomeric 3' overhangs are associated with telomere dysfunction in Hoyeraal-Hreidarsson syndrome. PLOS ONE 2009, 4:e5666.
88. Lee H.W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W., Depinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 1998, 392:569-574.
89. Liu L., Bailey S.M., Okuka M., Munoz P., Li C., Zhou L., Wu C., Czerwiec E., Sandler L., Seyfang A., Blasco M.A., Keefe D.L. Telomere lengthening early in development. Nature Cell Biology 2007, 9:1436-1441.
90. Maser R.S., Depinho R.A. Connecting chromosomes, crisis, and cancer. Science 2002, 297:565-569.
91. Mason P.J., Bessler M. The genetics of dyskeratosis congenita. Cancer Genetics 2011, 204:635-645.
92. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007, 448:375-379.
93. Matheu A., Maraver A., Collado M., Garcia-Cao I., Canamero M., Borras C., Flores J.M., Klatt P., Vina J., Serrano M. Anti-aging activity of the Ink4/Arf locus. Aging Cell 2009, 8:152-161.
94. Meier U.T. The many facets of H/ACA ribonucleoproteins. Chromosoma 2005, 114:1-14.
95. Mercken E.M., Carboneau B.A., Krzysik-Walker S.M., de C.R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Research Reviews 2011, 11:390-398.
96. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
97. Mitchell J.R., Cheng J., Collins K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3' end. Molecular and Cellular Biochemistry 1999, 19:567-576.
98. Mochizuki Y., He J., Kulkarni S., Bessler M., Mason P.J. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10756-10761.
99. Morelli M.A., Werling U., Edelmann W., Roberson M.S., Cohen P.E. Analysis of meiotic prophase I in live mouse spermatocytes. Chromosome Research 2008, 16:743-760.
100. Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132:598-611.
101. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxidants and Redox Signaling 2009, 11:59-98.
102. Nabetani A., Ishikawa F. Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. The Journal of Biochemistry 2011, 149:5-14.
103. Nelson N.D., Bertuch A.A. Dyskeratosis congenita as a disorder of telomere maintenance. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2012, 730:43-51.
104. Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. Journal of Theoretical Biology 1973, 41:181-190.
105. Orsted D.D., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. Journal of Experimental Medicine 2007, 204:1295-1301.
106. Palm W., de L.T. How shelterin protects mammalian telomeres. Annual Review of Genetics 2008, 42:301-334.
107. Pampalona J., Soler D., Genesca A., Tusell L. Telomere dysfunction and chromosome structure modulate the contribution of individual chromosomes in abnormal nuclear morphologies. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2010, 683:16-22.
108. Pampalona J., Soler D., Genesca A., Tusell L. Whole chromosome loss is promoted by telomere dysfunction in primary cells. Genes, Chromosomes and Cancer 2010, 49:368-378.
109. Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M., Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D., Nusse R., McCrea P.D., Artandi S.E. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460:66-72.
110. Peltomaki P. Mutations and epimutations in the origin of cancer. Experimental Cell Research 2012, 318:299-310.
111. Prescott J., Wentzensen I.M., Savage S.A., De V.I. Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2012, 730:75-84.
112. Prieur A., Peeper D.S. Cellular senescence in vivo: a barrier to tumorigenesis. Current Opinion in Cell Biology 2008, 20:150-155.
113. Rajaraman S., Choi J., Cheung P., Beaudry V., Moore H., Artandi S.E. Telomere uncapping in progenitor cells with critical telomere shortening is coupled to S-phase progression in vivo. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17747-17752.
114. Ratajczak M.Z., Zuba-Surma E.K., Machalinski B., Ratajczak J., Kucia M. Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Reviews and Reports 2008, 4:89-99.
115. Riyaz A., Riyaz N., Jayakrishnan M.P., Mohamed Shiras P.T., Ajith Kumar V.T., Ajith B.S. Revesz syndrome. Indian Journal of Pediatrics 2007, 74:862-863.
116. Rossi D.J., Bryder D., Seita J., Nussenzweig A., Hoeijmakers J., Weissman I.L. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 2007, 447:725-729.
117. Roth A., Harley C.B., Baerlocher G.M. Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results in Cancer Research 2010, 184:221-234.
118. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., Depinho R.A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999, 96:701-712.
119. Ruggero D., Grisendi S., Piazza F., Rego E., Mari F., Rao P.H., Cordon-Cardo C., Pandolfi P.P. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 299:259-262.
120. Savage S.A., Giri N., Jessop L., Pike K., Plona T., Burdett L., Alter B.P. Sequence analysis of the shelterin telomere protection complex genes in dyskeratosis congenita. Journal of Medical Genetics 2011, 48:285-288.
121. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
122. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. European Journal of Cancer 1997, 33:787-791.
123. Shay J.W., Pereira-Smith O.M., Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Experimental Cell Research 1991, 196:33-39.
124. Shkreli M., Sarin K.Y., Pech M.F., Papeta N., Chang W., Brockman S.A., Cheung P., Lee E., Kuhnert F., Olson J.L., Kuo C.J., Gharavi A.G., D'Agati V.D., Artandi S.E. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nature Medicine 2012, 18:111-119.
125. Sikora E., Arendt T., Bennett M., Narita M. Impact of cellular senescence signature on ageing research. Ageing Research Reviews 2011, 10:146-152.
126. Stadler Z.K., Vijai J., Thom P., Kirchhoff T., Hansen N.A., Kauff N.D., Robson M., Offit K. Genome-wide association studies of cancer predisposition. Hematology/Oncology Clinics of North America 2010, 24:973-996.
127. Strong M.A., Vidal-Cardenas S.L., Karim B., Yu H., Guo N., Greider C.W. Phenotypes in mTERT/and mTERT/mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Molecular and Cellular Biochemistry 2011, 31:2369-2379.
128. Takai H., Smogorzewska A., de L.T. DNA damage foci at dysfunctional telomeres. Current Biology 2003, 13:1549-1556.
129. Takai K.K., Kibe T., Donigian J.R., Frescas D., de L.T. Telomere protection by TPP1/POT1 requires tethering to TIN2. Molecular Cell 2011, 44:647-659.
130. Tomas-Loba A., Flores I., Fernandez-Marcos P.J., Cayuela M.L., Maraver A., Tejera A., Borras C., Matheu A., Klatt P., Flores J.M., Vina J., Serrano M., Blasco M.A. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008, 135:609-622.
131. Toussaint O., Medrano E.E., von Z.T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Experimental Gerontology 2000, 35:927-945.
132. Touzot F., Callebaut I., Soulier J., Gaillard L., Azerrad C., Durandy A., Fischer A., de Villartay J.P., Revy P. Function of Apollo (SNM1B) at telomere highlighted by a splice variant identified in a patient with Hoyeraal-Hreidarsson syndrome. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:10097-10102.
133. Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M., Veenstra T.D., Terns M.P., Artandi S.E. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323:644-648.
134. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
135. Vidal-Cardenas S.L., Greider C.W. Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase. Nucleic Acids Research 2010, 38:60-71.
136. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer 2008, 8:755-768.
137. Vulliamy T., Marrone A., Szydlo R., Walne A., Mason P.J., Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genetics 2004, 36:447-449.
138. Vulliamy T., Beswick R., Kirwan M.J., Hossain U., Walne A.J., Dokal I. Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component, TIN2. Clinical Genetics 2012, 81:76-81.
139. Vulliamy T.J., Knight S.W., Mason P.J., Dokal I. Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. Blood Cells, Molecules and Diseases 2001, 27:353-357.
140. Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006, 107:2680-2685.
141. Vulliamy T.J., Kirwan M.J., Beswick R., Hossain U., Baqai C., Ratcliffe A., Marsh J., Walne A., Dokal I. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLOS ONE 2011, 6:e24383.
142. Walne A.J., Vulliamy T., Beswick R., Kirwan M., Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008, 112:3594-3600.
143. Walne A.J., Vulliamy T., Beswick R., Kirwan M., Dokal I. Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome. Human Molecular Genetics 2010, 19:4453-4461.
144. Weinrich S.L., Pruzan R., Ma L., Ouellette M., Tesmer V.M., Holt S.E., Bodnar A.G., Lichtsteiner S., Kim N.W., Trager J.B., Taylor R.D., Carlos R., Andrews W.H., Wright W.E., Shay J.W., Harley C.B., Morin G.B. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genetics 1997, 17:498-502.
145. Westin E.R., Aykin-Burns N., Buckingham E.M., Spitz D.R., Goldman F.D., Klingelhutz A.J. The p53/p21(WAF/CIP) pathway mediates oxidative stress and senescence in dyskeratosis congenita cells with telomerase insufficiency. Antioxidants and Redox Signaling 2011, 14:985-997.
146. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nature Reviews Cancer 2009, 9:95-107.
147. Wong J.M., Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes and Develpoment 2006, 20:2848-2858.
148. Wong J.M., Kyasa M.J., Hutchins L., Collins K. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Human Genetics 2004, 115:448-455.
149. Wong K.K., Maser R.S., Bachoo R.M., Menon J., Carrasco D.R., Gu Y., Alt F.W., Depinho R.A. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 2003, 421:643-648.
150. Wright D.L., Jones E.L., Mayer J.F., Oehninger S., Gibbons W.E., Lanzendorf S.E. Characterization of telomerase activity in the human oocyte and preimplantation embryo. Molecular Human Reproduction 2001, 7:947-955.
151. Wright W.E., Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Experimental Gerontology 1992, 27:383-389.
152. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Developmental Genetics 1996, 18:173-179.
153. Wu P., van O.M., Rooney S., de L.T. Apollo contributes to G overhang maintenance and protects leading-end telomeres. Molecular Cell 2010, 39:606-617.
154. Xu J., Yang X. Telomerase activity in bovine embryos during early development. Biology of Reproduction 2000, 63:1124-1128.
155. Xu Y., He K., Goldkorn A. Telomerase targeted therapy in cancer and cancer stem cells. Clinical Advances in Hematology and Oncology 2011, 9:442-455.
156. Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M., Chanock S.J., Lansdorp P.M., Young N.S. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New England Journal of Medicine 2005, 352:1413-1424.
157. Yang D., He Q., Kim H., Ma W., Songyang Z. TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase. The Journal of Biological Chemistry 2011, 286:23022-23030.
158. Ye J., Lenain C., Bauwens S., Rizzo A., Saint-Leger A., Poulet A., Benarroch D., Magdinier F., Morere J., Amiard S., Verhoeyen E., Britton S., Calsou P., Salles B., Bizard A., Nadal M., Salvati E., Sabatier L., Wu Y., Biroccio A., Londono-Vallejo A., Giraud-Panis M.J., Gilson E. TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell 2010, 142:230-242.
159. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
160. Yu G.L., Bradley J.D., Attardi L.D., Blackburn E.H. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 1990, 344:126-132.
161. Zhang Y., Morimoto K., Danilova N., Zhang B., Lin S. Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing. PLOS ONE 2012, 7:e30188.
162. Zhao Z., Zuber J., Diaz-Flores E., Lintault L., Kogan S.C., Shannon K., Lowe S.W. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes and Develpoment 2010, 24:1389-1402.
163. Zhong F., Savage S.A., Shkreli M., Giri N., Jessop L., Myers T., Chen R., Alter B.P., Artandi S.E. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes and Development 2011, 25:11-16.
164. Zinsser F. Atrophia cutis reticularis cum pigmentations, dystrophia unguium et leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi). Ikonogr Dermat 1910, 5:219-223.